CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

About this update from Cormedix Inc.

[{"type":"image","alt":"CorMedix, Inc.","displaySize":"","headline":null,"caption":"CorMedix, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":151,"url":"https://media.zenfs.com/en/globenewswire.com/04a828931a8de73e15b3cb965f763d93"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C_G0R9JUmQlTsNvTh1B0Vw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/04a828931a8de73e15b3cb965f763d93","width":300,"height":151}},"lazy":false},{"type":"text","content":"‒ Q4 2025 Net Revenue of $128.6 million ‒","length":41,"tagName":"p"},{"type":"text","content":"‒ Pro Forma Full Year 2025 Net Revenue of $401.3 million ‒","length":58,"tagName":"p"},{"type":"text","content":"‒ Q4 2025 Net Income of $14.0 million; Adjusted EBITDA of $77.2 million ‒","length":73,"tagName":"p"},{"type":"text","content":"‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒","length":65,"tagName":"p"},{"type":"text","content":"PARSIPPANY, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on its business.","length":354,"tagName":"p"},{"type":"text","content":"Recent Corporate Highlights:","length":28,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"CorMedix announces $128.6 million of net revenue for the fourth quarter of 2025, largely driven by continued utilization of DefenCath by its outpatient dialysis customers. DefenCath sales contributed $91.2 million of net revenue in the quarter.","length":244,"tagName":"p"}]},{"val":[{"type":"text","content":"For the full-year 2025, CorMedix achieved total revenue of $311.7 million and pro forma total revenue of $401.3 million.(1)","length":123,"tagName":"p"}]},{"val":[{"type":"text","content":"In the fourth quarter of 2025, the Company recognized Net Income of $14.0 million and adjusted EBITDA of $77.2 million.(2) Basic and Fully Diluted EPS were $0.18 and $0.16 per share, respectively.","length":196,"tagName":"p"}]},{"val":[{"type":"text","content":"CorMedix reiterates previously established guidance for 2026, including net revenue of between $300 and $32...

More updates from Cormedix Inc.